Gilead Science’s COVID19 drug could rake in $2 to $3 billion in 2020-2021
In a significant development, Gilead Sciences Inc said, it expects to be able to produce twice the quantity of its coronavirus fighting drug remdesivir to COVID-19 patients by the end of this year. It expects to serve to at least 2 million COVID-19 patients by this time frame. Gilead hopes to start trials of an…









